SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's launches Carboprost Tromethamine Injection USP

03 Jul 2019 Evaluate

Dr. Reddy's Laboratories has launched Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate injection, 250 mcg/mL, approved by the US Food and Drug Administration (USFDA).

The Hemabate injection, 250 mcg/mL brand had US sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.

Dr. Reddy's Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1328.05 -5.00 (-0.38%)
24-Apr-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.80
Dr. Reddys Lab 1328.05
Cipla 1288.80
Zydus Lifesciences 930.20
Lupin 2269.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×